Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer
{{output}}
Introduction: The primary analysis of IMscin002 (NCT05171777) demonstrated that most patients preferred atezolizumab subcutaneous (SC) administration over intravenous (IV) administration; we report patient preference according to... ...
